Drug General Information (ID: DDICBZQA25)
Drug Name			Ivabradine		Drug Info		Relugolix		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Cardiovascular Agents				Gonadotropin-Releasing Hormone Antagonists
Structure

Mechanism of Ivabradine-Relugolix Interaction (Severity Level: Major)
Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Drug Name		Ivabradine				Relugolix
Mechanism		Bradycardia				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Ivabradine and Relugolix

Recommended Action
Management		Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided. Caution and cardiac monitoring are recommended if concomitant use is required.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Mittal SR "Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine." J Assoc Physicians India 62 (2014): 426-7. [PMID: 25438492]
3	Product Information. Corlanor (ivabradine). Amgen USA, Thousand Oaks, CA.